Literature DB >> 17312068

Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET.

Frank H Miller1, Ana L Keppke, Denise Reddy, Jie Huang, Jianhua Jin, Mary F Mulcahy, Riad Salem.   

Abstract

OBJECTIVE: Yttrium-90 radioembolization is an emerging treatment for liver malignancies. The purpose of this study was to evaluate the imaging response of liver metastases to 90Y microspheres based on size and necrosis criteria using CT and comparing the results to PET and to describe imaging features related to 90Y therapy.
MATERIALS AND METHODS: We reviewed the imaging studies of 42 patients with unresectable liver metastases treated with lobar radioembolization with 90Y. CT response was determined using traditional size criteria (World Health Organization [WHO] and Response Evaluation Criteria in Solid Tumors [RECIST]), necrosis criteria, and combined criteria (RECIST and necrosis). We compared the response on CT with the response on PET. Complications of treatment were assessed.
RESULTS: The response rate was 19% (8/42) by WHO criteria, 24% (10/42) by RECIST, 45% (19/42) by necrosis criteria, and 50% (21/42) by combined criteria. Stabilization of lesion size occurred in 50% of patients. Necrosis and combined criteria identified responders earlier than RECIST and WHO criteria. Seven responders by combined criteria had an increase in lesion size on initial follow-up and would have been considered nonresponders. PET scans were obtained in 23 patients (33 treated lobes). PET detected significantly more responses to treatment (21/33, 63%) than CT using RECIST (2/33, 6%) or combined criteria (8/33, 24%) (p < 0.05, McNemar test). Complications of treatment included radiation cholecystitis (10 patients, 23%) and liver edema (18 patients, 42%).
CONCLUSION: The use of necrosis and size criteria on CT and correlation with PET may improve the accuracy of assessment of response to 90Y treatment in patients with liver metastases and detect response earlier than standard size criteria.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17312068     DOI: 10.2214/AJR.06.0707

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  28 in total

Review 1.  Intra-arterial brachytherapy of hepatic malignancies: watch the flow.

Authors:  Bruno Morgan; Andrew S Kennedy; Val Lewington; Bleddyn Jones; Ricky A Sharma
Journal:  Nat Rev Clin Oncol       Date:  2010-10-05       Impact factor: 66.675

2.  Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times.

Authors:  Kenichiro Enooku; Ryosuke Tateishi; Fumihiko Kanai; Yuji Kondo; Ryota Masuzaki; Tadashi Goto; Shuichiro Shiina; Haruhiko Yoshida; Masao Omata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2011-09-21       Impact factor: 7.527

3.  Treatment planning and volumetric response assessment for Yttrium-90 radioembolization: semiautomated determination of liver volume and volume of tumor necrosis in patients with hepatic malignancy.

Authors:  Wayne L Monsky; Armando S Garza; Isaac Kim; Shaun Loh; Tzu-Chun Lin; Chin-Shang Li; Jerron Fisher; Parmbir Sandhu; Vishal Sidhar; Abhijit J Chaudhari; Frank Lin; Larry-Stuart Deutsch; Ramsey D Badawi
Journal:  Cardiovasc Intervent Radiol       Date:  2010-08-04       Impact factor: 2.740

4.  Can imaging patterns of neuroendocrine hepatic metastases predict response yttruim-90 radioembolotherapy?

Authors:  Julia Neperud; Armeen Mahvash; Naveen Garg; Ravi Murthy; Janio Szklaruk
Journal:  World J Radiol       Date:  2013-06-28

5.  Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases.

Authors:  Andrew S Kennedy; David S Ball; Steven J Cohen; Michael Cohn; Douglas M Coldwell; Alain Drooz; Eduardo Ehrenwald; Samir Kanani; Charles W Nutting; Fred M Moeslein; Samuel G Putnam; Steven C Rose; Michael A Savin; Sabine Schirm; Navesh K Sharma; Eric A Wang
Journal:  J Gastrointest Oncol       Date:  2015-12

6.  Agreement between competing imaging measures of response of hepatocellular carcinoma to yttrium-90 radioembolization.

Authors:  Eugene Duke; Jie Deng; Saad M Ibrahim; Robert J Lewandowski; Robert K Ryu; Kent T Sato; Frank H Miller; Laura Kulik; Mary F Mulcahy; Andrew C Larson; Riad Salem; Reed A Omary
Journal:  J Vasc Interv Radiol       Date:  2010-02-20       Impact factor: 3.464

7.  Evaluation of hepatic tumor response to yttrium-90 radioembolization therapy using texture signatures generated from contrast-enhanced CT images.

Authors:  Rebekah H Gensure; David J Foran; Vincent M Lee; Vyacheslav M Gendel; Salma K Jabbour; Darren R Carpizo; John L Nosher; Lin Yang
Journal:  Acad Radiol       Date:  2012-07-26       Impact factor: 3.173

8.  Short-term effectiveness of radiochemoembolization for selected hepatic metastases with a combination protocol.

Authors:  Shahram Akhlaghpoor; Alireza Aziz-Ahari; Mahasti Amoui; Shahnaz Tolooee; Hossein Poorbeigi; Shahab Sheybani
Journal:  World J Gastroenterol       Date:  2012-10-07       Impact factor: 5.742

Review 9.  [Therapy response of liver tumors after selective internal radiation therapy].

Authors:  T F Jakobs; R T Hoffmann; K Tatsch; C Trumm; M F Reiser
Journal:  Radiologe       Date:  2008-09       Impact factor: 0.635

10.  Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases.

Authors:  Vankadari Kousik; Pankaj Promila; Ritu Verma; Arun Gupta
Journal:  Indian J Gastroenterol       Date:  2016-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.